430 related articles for article (PubMed ID: 34504023)
1. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
3. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
[TBL] [Abstract][Full Text] [Related]
4. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
[TBL] [Abstract][Full Text] [Related]
5. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Hao Q; Kanda M; Tani Y
BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
[TBL] [Abstract][Full Text] [Related]
7. Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
van Lierop ZY; Wieske L; Koel-Simmelink MJ; Chatterjee M; Dekker I; Leurs CE; Willemse EA; Moraal B; Barkhof F; Eftimov F; Uitdehaag BM; Killestein J; Teunissen CE
Mult Scler; 2022 Jan; 28(1):102-110. PubMed ID: 33890520
[TBL] [Abstract][Full Text] [Related]
8. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
10. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
Mult Scler Relat Disord; 2024 Jun; 88():105701. PubMed ID: 38889559
[TBL] [Abstract][Full Text] [Related]
11. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: A systematic review and meta-analysis.
Liu N; Sun M; Zhang W; Sun J; Gong P; Wang H; Wang M
J Clin Neurosci; 2022 Jul; 101():198-203. PubMed ID: 35617924
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
[TBL] [Abstract][Full Text] [Related]
14. Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
van Lierop ZY; Noteboom S; Steenwijk MD; van Dam M; Toorop AA; van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Teunissen CE; Killestein J
Mult Scler; 2022 Dec; 28(14):2231-2242. PubMed ID: 36062492
[TBL] [Abstract][Full Text] [Related]
15. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
[TBL] [Abstract][Full Text] [Related]
16. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study 'TOPICS Greece'.
Efthimios D; Georgios K; Antonia A; Rania G; Maria-Eleutheria E;
Clin Drug Investig; 2021 Oct; 41(10):865-874. PubMed ID: 34427893
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
20. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
